AUSTIN, Texas, June 1, 2016 /PRNewswire/ -- Luminex Corporation today announced that it has received CE-IVD status under the European Directive on In Vitro Diagnostic Medical Devices for the ARIES(®) Flu A/B & RSV Assay. Designed for use with the FDA cleared and CE-IVD marked ARIES(®) System, the ARIES(®) Flu A/B & RSV Assay is a rapid and accurate method for the detection and differentiation of three key respiratory pathogens: influenza A virus, influenza B virus, and respiratory syncytial virus (RSV) using a sample to answer platform.
Photo - http://photos.prnewswire.com/prnh/20160531/373627 [http://photos.prnewswire.com/prnh/20160531/373627] Photo - http://photos.prnewswire.com/prnh/20160531/373628 [http://photos.prnewswire.com/prnh/20160531/373628] Logo - http://photos.prnewswire.com/prnh/20150201/172702LOGO [http://photos.prnewswire.com/prnh/20150201/172702LOGO]
"The ARIES(®) Flu A/B & RSV Assay provides a rapid, automated and cost-effective way to inform actionable treatment decisions and manage outbreaks in markets accepting CE marking for clinical use," said Thomas Pracht, Luminex's Managing Director for EMEIA. "Combined with our comprehensive respiratory test menu, we believe the ARIES(®) Flu A/B & RSV Assay provides the most flexible and complete clinical algorithm for improved patient outcomes."
This is the second assay this year for which Luminex has received CE-IVD marking for use on the new ARIES(®) System. The company received CE-IVD marking for the ARIES(®) HSV 1&2 Assay in March 2016, and FDA clearance in October 2015, along with clearance of the ARIES(®) instrument system.
To learn more or request a demo, please visit: http://www.luminexcorp.com/ARIES [http://www.luminexcorp.com/ARIES].
About the ARIES(®) System and Flu A/B & RSV Assay The ARIES(®) System is a sample to answer molecular diagnostic system designed to increase laboratory efficiency, ensure result accuracy, and fit seamlessly into today's lean laboratory environment. ARIES(®) uses internal barcode scanning and other advanced features to minimize operator errors. Two independent modules each support from one to six cassettes, allowing for both STAT and Batch testing of IVD and homebrew assays using MultiCode(®) Reagents when using a common Universal Assay Protocol. An integrated touchscreen PC eliminates the need for a separate computer, standalone keyboard, and mouse, maximizing valuable bench space.
The ARIES(®) Flu A/B & RSV Assay is a polymerase chain reaction (PCR) based qualitative in vitro diagnostic test for the direct detection and differentiation of influenza A virus, influenza B virus, and respiratory syncytial virus (RSV) nucleic acid from nasopharyngeal swabs (NPS) specimens from patients with signs and symptoms of respiratory tract infection in conjunction with clinical and laboratory findings.
About Luminex CorporationLuminex is committed to applying its passion for innovation toward creating breakthrough solutions to improve health and advance science. The company is transforming global healthcare and life-science research through the development, manufacturing and marketing of proprietary instruments and assays utilizing xMAP(®) open-architecture multi-analyte platform, MultiCode(®) real-time polymerase chain reaction (PCR), and multiplex PCR-based technologies, that deliver cost-effective rapid results to clinicians and researchers. Luminex's technologies are commercially available worldwide and in use in leading clinical laboratories, as well as major pharmaceutical, diagnostic, biotechnology and life science companies. Luminex is meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, biodefense research and food safety. For further information on Luminex Corporation and the latest advances in multiplexing using award winning technology, please visit http://www.luminexcorp.com/ [http://www.luminexcorp.com/].
Statements made in this release that express Luminex's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. Forward-looking statements in this release include statements regarding the available market for ARIES(®), future revenue growth anticipated for ARIES(®), and the development, testing and regulatory approval progress of our pipeline products, including ARIES(®) related assays. The words "believe", "expect", "intend", "anticipates", "confident", "will", "could", "should", and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results or performance could differ materially from those anticipated in such forward-looking statements. Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, our ability to launch products on time, the timing of regulatory approvals, the outcome of clinical trials as well as the risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission. The forward looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Investor Contact Harriss Currie, 512.219.8020 Sr. Vice President of Finance and CFO email@example.com [mailto:firstname.lastname@example.org]
Media Contact Christine Valle, 512.219.8020Sr. Manager, Global Marketingcvalle@luminexcorp.com [mailto:email@example.com]
Web site: http://www.luminexcorp.com/